Comparative effectiveness of Cladribine tablets vs other drugs in relapsing-remitting multiple sclerosis: an approach merging randomized controlled trial with real life data by Signori, A et al.
14 December 2021
AperTO - Archivio Istituzionale Open Access dell'Università di Torino
Original Citation:
Comparative effectiveness of Cladribine tablets vs other drugs in relapsing-remitting multiple sclerosis: an




(Article begins on next page)
Anyone can freely access the full text of works made available as "Open Access". Works made available under a
Creative Commons license can be used according to the terms and conditions of said license. Use of all other works
requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.
Availability:
SAGE PUBLICATIONS LTD
This is a pre print version of the following article:
This version is available http://hdl.handle.net/2318/1757448 since 2020-10-01T15:28:07Z
Abstract: P981 
 
Type: Poster Sessions 
 
Abstract Category: Therapy - Immunomodulation/Immunosuppression 
 
A. Signori1, F. Saccà2, R. Lanzillo2, G.T. Maniscalco3, E. Signoriello4, A. Repice5, P. Annovazzi6, D. Baroncini6, M. Clerico7, 
E. Binello8, R. Cerqua9, G. Mataluni10, P. Perini11, S. Bonavita4, L. Lavorgna4, I.R. Zarbo12, A. Laroni13,14, L.P. Gutierrez15, S. 
La Gioia16, B. Frigeni16, V. Barcella16, J. Frau17, E. Cocco17, G. Fenu17, V. Torri Clerici15, A. Sartori18, S. Rasia19, C. Cordioli19, 
M.L. Stromillo20, A. Di Sapio21, S. Pontecorvo22, R. Grasso23, S. Barone24, C. Barrilà25, C.V. Russo2, S. Esposito4, D. 
Ippolito4, D. Landi10, A. Visconti26, M.P. Sormani1,27 
 
1Department of Health Sciences - Section of Biostatistics, University of Genoa, Genoa, 2Department of Neurosciences, 
Reproductive Sciences and Odontostomatology, Multiple Sclerosis Center, Federico II University, 3Neurological Clinic 
and Multiple Sclerosis Center, AORN A.Cardarelli, 4University of Campania 'Luigi Vanvitelli', Naples, 5University of 
Florence, Firenze, 6ASST Valle Olona, Gallarate, 7University of Torino, San Luigi Gonzaga Hospital, Torino 
Orbassano, 8Ospedale Universitario Città della Salute e della Scienza di Torino, Torino, 9University Polytechnic Marche, 
Ancona, 10Policlinic Tor Vergata, Rome, 11University of Padua, Padua, 12University of Sassari, Sassari, 13University of 
Genoa, 14IRCCS San Martino-IST, Genoa, 15IRCCS Foundation Carlo Besta Neurological Institute, Milan, 16ASST Papa 
Giovanni XXIII, Bergamo, 17University of Cagliari, Cagliari, 18University of Trieste, Trieste, 19ASST Spedali Civili, 
Brescia, 20University of Siena, Siena, 21Regina Montis Regalis Hospital, Mondovì, 22Sapienza University, 
Rome, 23Neurologia Universitaria OORR, Foggia, 24University Magna Graecia of Catanzaro, Catanzaro, 25Valduce 
Hospital, Como, 26Medical Department, Merck Serono, Rome, 27IRCCS Ospedale Policlinico San Martino, Genoa, Italy 
 
Introduction: Cladribine tablets was tested against placebo in randomized controlled trials (RCT). 
Objective: To compare the effectiveness of Cladiribine tablets vs other approved drugs in relapsing-remitting multiple 
sclerosis (RRMS) naïve patients, by matching RCT to observational data. 
Methods: Naïve patients from the pivotal trial assessing Cladribine tablets vs placebo (CLARITY) were propensity-score 
matched to data from the Italian multicenter database i-MuST. This database included 3006 naïve patients diagnosed 
2010-2018 in 24 Italian MS centers who started a disease-modifying therapy. The annualized relapse-rate (ARR) over 2 
years from treatment start was compared between patients treated with Cladribine tablets and other approved drugs 
(Interferon, Glatiramer-Acetate, Fingolimod, Natalizumab, Dymethil-fumarate), having the comparisons with placebo as a 
reference. Treatment effects were estimated by an inverse-probability weighted (IPW) negative-binomial regression 
model. The treatment effect has been also evaluated according to disease activity (HDA: high disease activity defined as 
⩾2 relapses during the year prior to study entry). 
Results: From the i-MuST database a total of 1168 patients were treated with Interferon, 402 with Glatiramer-acetate, 
113 with Fingolimod, 149 with Natalizumab and 295 with Dymethil-fumarate. Patients' weighted characteristics resulted 
well balanced between groups. All the tested drugs had an effect vs placebo close to those detected in RCT. Patients 
treated with Cladribine tablets had a significantly lower ARR as compared with Interferon (RR=0.48;p< 0.001), 
Glatiramer-Acetate (RR=0.49;p< 0.001) and Dymethil-fumarate (RR=0.6;p=0.011), a comparable ARR with Fingolimod 
(RR=0.74;p=0.24) and a significantly higher ARR than Natalizumab (RR=2.13;p=0.014). The effect of Cladribine tablets 
low dose was amplified in HDA patients across all treatments except Fingolimod. 
Conclusions: In RRMS patients, Cladribine tablets showed lower ARR compared with matched patients who started 
another DMT, similar with fingolimod, behind natalizumab. The effect was amplified in the subgroup of HDA patients. 
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